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Abstract: In patients with diabetes mellitus type 1, the pancreatic insulin production ceases, causing 
raise in blood glucose level (BGL) and potentially severe long-term complications. The “holy grail” 
of diabetes treatment is the artificial pancreas (AP), a closed-loop control system that regulates the 
user’s BGL by infusing insulin, and possibly glucagon. Numerous attempts have been largely 
unsuccessful, mainly due to slow dynamics that make it difficult to avoid unwanted BGL 
excursions. System performance has been improved through improved sensor technology and 
faster-acting insulin types, but the risk of hypoglycemia is still significant unless the glucose 
setpoint is unnaturally high. 
We argue that this problem can be circumvented by choosing appropriate sites for glucose 
measurement and insulin infusion. While intravascular measurement and infusion provides the 
fastest dynamics and thus the best conditions for closed-loop control, it is only viable in inpatients 
mainly due to danger of infections and limited sensor durability. On the other extreme, state-of-
the-art subcutaneous systems exhibit significant time delays and diffusion dynamics, yielding poor 
BGL control in the event of disturbances like meals and physical activity. Avoiding dangerous 
hypoglycemia therefore comes at the expense of daily episodes of elevated BGL (typically 10–15 
mmol/L) that increase the risk of long-term complications. Furthermore, slow insulin uptake from 
subcutis remains as a major challenge. Hence we advocate the double intraperitoneal (IP) AP. 
Here, insulin is released into the abdominal cavity (peritoneum) through a semi-permanent port, 
which also allows access for IP glucose sensing. This improves both sensing and absorption 
dynamics. Thus the closed-loop control may be significantly tighter, allowing a setpoint closer to 
the healthy normal BGL of approximately 4.5 mmol/L whilst potentially improving system safety. 
These statements are supported by results from our own research and the literature.  
Keywords: Medical applications, artificial pancreas, dynamic modelling, time delay, time constants.  
1 INTRODUCTION 
Diabetes mellitus involves defective regulation of blood 
glucose levels (BGL), which can lead to serious or fatal 
complication both in the short and the long term. The “holy 
grail” of diabetes treatment is the artificial pancreas (AP), a 
closed-loop system that monitors the glucose level and 
infuses insulin, and possibly glucagon, according to an 
appropriate control law to keep the user’s BGL within 
appropriate limits. Numerous attempts have been largely 
unsuccessful, mainly due to slow open-loop system dynamics 
associated with the technology itself and the sites chosen for 
glucose measurement and insulin infusion, which limits the 
attainable closed-loop performance and robustness. Improved 
sensor technology and faster-acting insulin types have 
induced notable improvements in AP performance, and it 
now seems achievable to avoid most of the serious hyper- 
and hypoglycemic events through the use of a closed-loop 
system (Kropff et al. 2015b). However, there is an increasing 
understanding that a simple “time within range” 
consideration is insufficient as a treatment target, and that 
target ranges commonly applied are too wide, especially in 
the higher BGL range (DCCT/EDIC Research Group et al. 
2015, Hu et al. 2015). On these grounds we claim that all in 
all there is no well-functioning AP as of yet. 
In principle there are many ways to restore the glucose 
regulating function of a dysfunctional or missing pancreas. 
Complete organ transplantation is a given option, however 
with potentially severe consequences related to immune 
suppression and possible rejection of the transplanted organ 
(Redfield et al. 2015). Similar complications occur in 
methods based on implantation of pancreatic beta cells or 
stem cells (Johannesson et al. 2015, Soon-Shiong et al. 
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1992). Further explorations of these treatment options are 
outside the scope of this paper. 
The first experiments with an AP were performed in the early 
1970’s with a large device with significant limitations. 
However, the dream had been awakened, and a substantial 
and increasing number of clinical studies have been 
performed over the last decade. The theoretically ideal 
solution in which both glucose sensing and insulin infusion 
are performed intravascularly is infeasible in outpatients due 
to safety issues. Most studies are therefore based on 
subcutaneous (SC) continuous glucose monitoring (CGM) 
with enzymatic technology and SC insulin administration by 
use of insulin pumps. This “double SC approach” has certain 
physiological limitations that hamper the possibilities for a 
well-functioning robust AP able to maintain normal or close 
to normal BGL. In this paper we discuss these limitations and 
argue, based on basic concepts from control theory, that an 
AP in which both glucose measurement and insulin infusion 
take place in the peritoneal cavity, e.g. through a port similar 
to that used by Liebl et al. (2009), is a promising option.  
The rest of this paper is organized as follows: Section 2 
provides a brief discussion of the dynamics of an AP system 
in terms of its physical components and some basic notions 
that will be used in subsequent sections. Sections 3 and 4 
describe the SC and IP routes of insulin infusion and glucose 
measurement in terms of dynamics and safety. Section 5 
discusses the implications of the findings in terms of future 
AP systems and provides some concluding remarks. 
2 ON DYNAMICS 
For the purpose of a structured discussion, we will section the 
open-loop dynamics as follows (cf. Fig. 1): 
 Site dependent absorption dynamics – from insulin 
input to intravascular insulin concentration ([𝐼𝐼𝐼]),  
Site independent physiological dynamics – from [𝐼𝐼𝐼] to intravascular glucose concentration ([𝐺𝐼𝐼]), 
Site dependent physiological sensing dynamics – 
from [𝐺𝐼𝐼] to glucose concentration at the site of the sensor 
([𝐺𝑠𝑠𝑠𝑠]), 
Glucose sensor dynamics – from [𝐺𝑠𝑠𝑠𝑠] to sensor 
output ([𝐺𝐼𝐼]), i.e. the dynamics associated with the sensor 
technology itself. 
For the sake of completeness Fig. 1 also includes a block 
marked meal digestion, which represents the dynamics from 
meal input to blood glucose; here, 𝑅𝑎 represents the rate of 
appearance of meal related glucose in the bloodstream. As 
this is not part of the control loop and we consider systems 
without meal announcement (feed-forward), this block will 
not be treated any further. 
Some of the subsystems in Fig. 1 will be treated in more 
detail in later sections. Several of these systems are 
somewhat coupled, e.g. through nonlinear effects. However, 
this does not invalidate the general conclusions. The 
influence of insulin type and local factors like temperature 
and pressure are suggested by dashed lines. 
2.1 Time delays, time constants, and bandwidth 
Concepts such as time delays, time constants and bandwidth 
are essential for the following discussion. In order to make 
this text more accessible to a wide audience, we offer a brief 
explanation of these terms;  see e.g. Åstrøm and Murray 
(2014) for an introduction to the subject. 
Parts of this discussion strictly relates only to linear systems, 
while human insulin and glucose dynamics exhibit non-linear 
properties. The use of these notions in the present context is 
justified because the system in question is predominantly 
linear within its normal operating range, and thus can be well 
approximated by linear models (see e.g. Chee and Fernando 
(2007)).  
A time delay, also known as dead time, is typically associated 
with a transportation mechanism (e.g. blood transport), and 
denotes the time that passes from a stimulus is applied to a 
system until the first trace of the incident is theoretically 
detectable at the system’s output.  
A time constant can be associated with e.g. diffusion through 
a semipermeable barrier (like a cell membrane) separating 
two compartments, and relates to the time it takes to re-
establish an equilibrium following a sudden concentration 
gradient across the membrane. 
The bandwidth of a system is the frequency of the fastest 
oscillating sine wave that can be fed into the system’s input 
and subsequently be observed at its output without significant 
attenuation. The bandwidth of a system exhibiting a single 
time constant 𝑇 [s] is normally defined as 𝛽 = 1 𝑇⁄ [rad s⁄ ], 
so a larger time constant implies a lower bandwidth. 
Whereas the effect of a time constant in principle can be 
cancelled to any desirable accuracy by filtering of the output 
signal, a time delay cannot be negated in real time because it 
requires the prediction of future signal levels. Time delays 
 
Fig. 1. Insulin and glucose dynamics split into different sections. This figure is licensed under a Creative Commons BY-
NC-SA 4.0 license, hereafter abbreviated to CC BY-NC-SA. 
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and time constants limit the obtainable bandwidth (i.e. the 
usable frequency range) of a closed-loop system. In a system 
with multiple time delays and time constants it is the total of 
all time delays and the larger time constant(s) that constitute 
the limiting factors. It is therefore common to simplify the 
analysis by assuming that the system includes only one 
“equivalent” time constant and time delay, respectively.  
Following from the preceding discussion, time constants and 
delays in the control loop limit how quickly a closed-loop AP 
system can respond in order to correct BGL deviations; the 
lower the closed-loop bandwidth, the larger the glucose 
fluctuations. This fact is at the core of this paper’s message. 
In AP research literature the importance of dynamics is 
appreciated, but distinctions are only occasionally made 
between notions like time delays and time constants; the 
terms are frequently used interchangeably with other terms 
like time lag, latency, time to half-max etc., and are 
sometimes used ambiguously. In this paper we use the term 
latency to collectively denote bandwidth-limiting effects, 
including quantities for which the cited publication does not 
indicate clearly if it is a time delay, a time constant or another 
related phenomenon that is reported. 
3 INSULIN ADMINISTRATION 
3.1 Site dependent absorption dynamics 
Insulin can be infused or injected in different tissues. The 
pharmacokinetics of insulin is influenced by the site of 
insulin administration and the type, concentration and volume 
of the insulin solution, through the associated transportation, 
diffusion and biochemical processes. Attempts have been 
made to administer insulin both through inhalation and 
orally, with varying results (Sousa et al. 2015). However, 
infusion through syringes or catheters inserted in SC tissue is 
still the prevailing treatment solution. Among the more recent 
developments is that of faster-acting insulins. An overview of 
typical infusion insulin dynamics can be found in Evans et al. 
(2011) and Heise et al. (2015). The mathematical models of 
insulin dynamics have been reviewed by Wilinska et al. 
(2005). 
3.2 Subcutaneous insulin delivery; ISC 
The present clinical gold standard of insulin delivery is 
continuous SC delivery of short-term acting insulin by a 
pump, or multiple daily SC injections of medium long-term 
and short-term acting insulin (Hirsch 2005, Pickup 2012). 
The duration of the effect of injected insulin mostly depends 
on the rate of absorption from the SC tissue to the circulation. 
This may take more than 24 hours for some insulins, and 
even for the most fast acting types 90–120 min are needed to 
reach maximum glucose-lowering effect (Heise et al. 2015). 
This differs considerably from the physiologic situation, 
where insulin released from the pancreas arrives in the 
circulation within minutes after the BGL is increased. 
Important is also the lasting glucose lowering effect, which 
may continue even after circulating insulin levels have 
normalized. Taken together, this means that a SC injection of 
the fastest acting insulin analogue will have a glucose 
lowering effect for as much as 4–5 hours after it has been 
delivered (Evans et al. 2011, Heise et al. 2015). Due to slow 
absorption the maximum insulin effect on BGL may be 1–3 
hours after SC injections. For all practical purposes this 
means that the SC approach for insulin delivery is not 
compatible with a robust AP (Hovorka et al. 2006, Cobelli et 
al. 2011). Additionally, the insulin absorption rate and 
fraction of insulin absorbed are unpredictable due to changes 
to the local blood circulation and the tissue surrounding the 
infusion site. 
3.3 Intraperitoneal insulin delivery; IIP 
Intraperitoneal insulin infusion (IIP) has been applied with 
some success (Liebl et al. 2009, Renard et al. 2010). 
Physiologically, this option is quite appealing, and it has a 
fast dynamic effect. The pancreas secretes insulin to the liver 
via the portal vein, and a significant proportion of the insulin 
is absorbed by the liver (“first passage effect”) within a few 
seconds after secretion before the rest enters the systemic 
circulation according to studies in animals (Matsuo et al. 
2003, Micossi et al. 1986, Radziuk et al. 1994, Schade et al. 
1979, Schade et al. 1980, Schade et al. 1981, Selam et al. 
1990) and humans (Widerøe et al. 1996). IIP gives close to 
physiological insulin levels both in the liver and other tissues 
(Nelson et al. 1982). The liver responds to this insulin 
stimulus by inhibiting its glucose production and storing 
glucose as glycogen, and thus causing a primary and fast 
BGL reduction. The insulin that is not absorbed by the liver 
enters the systemic circulation and causes an increase in 
glucose uptake in the various tissues, thereby leading to a 
secondary BGL response. The overall result is a glucose 
lowering effect that is almost comparable to intravenous 
infusion in terms of bandwidth, and with a latency 
comparable to that of the glucose increasing effect of food 
intake (Schade et al. 1979). Consequently, it is possible to 
counteract the trend of an increasing BGL with a faster and 
increased glucose lowering effect of a given amount of 
insulin without increasing the risk of subsequent 
hypoglycemia compared to the risk associated with ISC 
delivery. This has a significant and desirable impact on the 
closed-loop control performance and reduces the dependence 
on feed-forward actions like meal announcements.  
The practical implementation of IIP can have at least two 
different forms, as illustrated in Fig. 2. The left part of the 
figure shows a partially implanted AP in which the insulin 
 
Fig. 2. Illustration of a partially implanted (left) and 
port-based (right) intraperitoneal AP. CC BY-NC-SA. 
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pump and reservoir (P) are connected wirelessly to an 
external control unit (C) with a subcutaneous glucose sensor. 
This resembles the system described e.g. by Lee et al. (2014). 
The right-hand figure illustrates the concept of a port-based 
intraperitoneal AP, in which a combined controller and 
hormone pump (C/P) resides externally to the body. Insulin 
infusion and glucose sensing are performed with slender and 
retractable components through a semi-permanent port 
through the abdominal wall. The size of the port has been 
exaggerated for clarity; the port can be similar to the DiaPort 
(Roche Diagnostics, Basel, Switzerland), adapted to 
accommodate the glucose sensing components. 
3.4 Safety issues and comparison (ISC vs. IIP) 
Because of the slow uptake to the circulation, SC insulin 
delivery carries a particular risk of overdosing e.g. in 
conjunction with postprandially elevated BGL. By the time, 
the BGL has returned to the normoglycemic range, already 
delivered insulin may still be released from the SC tissue, 
reducing the BGL even further. This may lead to 
hypoglycemia. If this is treated with carbohydrate intake, one 
can easily induce over-treatment that brings BGL back into 
the hyperglycemic range. Large deviations from desirable 
glucose levels as well as adiposity due to increased overall 
caloric intake are potential results.  
Suggested countermeasures include “insulin-on-board 
constraints” (Ellingsen et al. 2009) to prevent insulin 
overdosing, and feed-forward of meals, i.e. input/predictions 
from the user. However, relying on the user’s meal prediction 
is in itself a large safety hazard in that the user may 
overestimate a meal, or the meal may be delayed or even 
cancelled completely. Both of these cases could end up with 
serious hypoglycemias. 
The comparative benefit of the IIP option is quite obvious: the 
amount of insulin that is infused in the patient but not yet 
distributed through circulation is reduced, and thus BGL 
oscillations can more easily be avoided.  
Fault detection is another important issue with respect to 
safety of an AP. Information about faults is mainly derived 
by comparing CGM data with the expected response to the 
given insulin infusion. IIP potentially involves less local tissue 
irritation, less clotting and more predictable insulin 
absorption compared to the ISC route (Liebl et al. 2009, 
Renard et al. 2010, Schaepelynck Bélicar et al. 2003). Thus, 
one can expect faster detection of insulin infusion system 
failures, e.g. an obstruction of the infusion set. 
One could argue that the faster insulin uptake from the IP 
infusion site to the blood stream (Schade et al. 1979, Schade 
et al. 1980) makes it more dangerous, because insulin 
delivered this way affects the BGL more rapidly and with a 
stronger peak effect. On the other hand, the faster effect 
allows for a higher closed-loop bandwidth, which in normal 
situations implies smaller transient BGL deviations and thus 
generally improves safety and robustness. The balance of 
these effects requires further investigation. 
 
 
 
4 GLUCOSE MEASUREMENT 
4.1 Glucose sensing dynamics 
Glucose concentration can in principle be measured in all 
tissues. In order to be measureable, glucose in the blood must 
be transported through tissue and fluids by diffusion and/or 
active cellular transport mechanisms, and establish a 
representative concentration in the immediate vicinity of the 
sensing element. This constitutes what is denoted site 
dependent physiological sensing dynamics in Fig. 1 (Basu et 
al. 2013, Basu et al. 2015). In addition to this, the sensor 
technology has dynamical properties in and of itself, 
corresponding to the block named glucose sensor dynamics 
in the same figure. These phenomena arise from elements 
such as protective membranes through which the glucose 
must diffuse in order to reach the sensing element, and 
enzymatic and electrochemical reactions in the element. 
Further latency and discretization effects may be added by 
the associated software, which typically employs integration 
or filtering of the raw sensor signal over several minutes in 
order to suppress measurement noise. 
4.2 Subcutaneous glucose measurement; GSC 
Commercially available CGM units employ sensors that are 
placed in SC tissue. The resulting site dependent 
physiological sensing dynamics from intravascular glucose to 
interstitial glucose surrounding the sensor includes a latency 
of at least 6–7 minutes (Basu et al. 2013, Basu et al. 2015). 
Local skin temperature may influence the local blood flow 
and there is also the effect of local pressure on the tissue 
restricting local blood circulation, both potentially changing 
the dynamics.  
Most current sensors for CGM are enzyme-based with 
essentially unknown device specific glucose sensor 
dynamics. At present, most CGMs give glucose values that 
are averaged over 5 minutes, a figure that is not unlikely to 
improve as sensor technology is further refined. Burnett et al. 
(2014) identified the collective effect of site dependent 
physiological sensing dynamics and glucose sensor 
dynamics, and found a mean time delay and time constant for 
GSC of as much as 1.4 min and 12.4 min, respectively.  
Among the more practical drawbacks of current CGM 
technology are the limited lifetime of each sensor (usually in 
the range 6–8 days) and in particular the limited accuracy of 
glucose measurements in the low normal and normal range 
(Kropff et al. 2015a). Additionally, typical sensors need to be 
calibrated during normal operation at least two times daily to 
compensate for signal drift (Keenan et al. 2011).  
4.3 Intraperitoneal glucose measurement; GIP 
The possibility of continuous IP glucose measurement has 
only been studied a few times in animals (Burnett et al. 2014, 
Clark et al. 1988, Clark et al. 1987, Fougner et al. submitted, 
Velho et al. 1989). 
Our pilot animal studies (Fougner et al. submitted) show that 
the GIP time delay is in the range 0–26 s (mean: 9.7 s), while 
the time constant was found to be 0.5–10.2 min (mean: 4.7 
min) for the site dependent physiological sensing dynamics 
alone (i.e. after the sensor’s intrinsic time constant had been 
compensated for). In comparison, Burnett et al. (2014) found 
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a mean time delay and time constant for GIP of 0.68 min and 
5.6 min, respectively; these numbers relate to the collective 
effect of the site dependent physiological sensing dynamics 
and the unknown glucose sensor dynamics, and are in general 
agreement with our findings. IP glucose sensing sites thus 
have substantially faster dynamics than SC sites. 
At present, insulin absorption is a far more severe bottleneck 
than glucose sensing, but as faster insulins and faster infusion 
methods (e.g. IIP) are adopted, the sensing (site dependent as 
well as sensor specific) dynamics will become increasingly 
important as a limiting factor.  
4.4 Safety issues and comparison (GSC vs. GIP) 
Important properties of a closed-loop control system are the 
accuracy and reliability of sensor readings. Common glucose 
oxidase sensors used for SC measurement are frequently 
impaired by transient pressure induced sensor attenuation 
(PISA). This occurs in particular during night when the 
patient is lying on the sensor (Helton et al. 2011) and leads to 
decreased glucose readings. Recent miniaturization of sensors 
may have reduced this predominantly mechanical problem. 
Most sensor augmented insulin pump systems on the market 
incorporate an automatic shut-off algorithm that stops insulin 
delivery when BGL falls below a threshold to prevent 
hypoglycemia. However, pump shut-offs based on 
erroneously low sensor readings result in hyperglycemia (e.g. 
Baysal et al. (2014)).). As in the cases described above, large 
BGL oscillations may result. 
Sensors located in the peritoneum are largely protected 
against externally induced mechanical stress. Depending on 
the sensing technology, this may reduce the problems of 
PISA and thus significantly improve the reliability of sensor 
readings. However, it may be difficult to control exactly 
where the tip of the catheter resides, and it can get stuck in 
the peritoneal wall or fatty tissue during insertion or later. 
This may affect the measurement dynamics as well as the 
insulin absorption in a yet unpredictable way. The possible 
influence of bowel and body movements and changing intra-
abdominal pressure also needs to be established. 
The body reacts to SC sensors with encapsulation, fouling 
and inflammation, impairing the sensor performance in an 
unpredictable manner (Helton et al. 2011). Experiences with 
IP implants have shown that the foreign body response is less 
acute in the peritoneal cavity (Haveman et al. 2010). This 
may translate to less dynamical changes in the case of IP 
sensing and consequently to more reliable sensor readings. 
One could also foresee a reduced need for sensor 
recalibrations.  
Concerning sensor faults, physical redundancy is an obvious 
way to increase the system’s reliability, but two or more SC 
sensors are inconvenient and not likely to be accepted by 
most patients (Doyle et al. 2014). A port to the peritoneal 
cavity, on the other hand, has the potential to allow the use of 
redundant sensors without the need for additional punctures. 
Sensed glucose concentration may differ from actual BGL, a 
fault that can cause the whole AP to fail. It is therefore 
essential for a safe AP to detect deviations from normal 
behavior as soon as possible. Information about sensor faults 
is obtained by comparing CGM data with statistical 
knowledge or with expected glucose change for the given 
insulin infusion. Due to the faster glucose sensing dynamics 
(Burnett et al. 2014, Fougner et al. submitted), as well as 
faster insulin infusion dynamics, as described above, the IP 
approach is expected to allow earlier detection of both insulin 
infusion faults and sensor faults alike. 
5 DISCUSSION 
In addition to the benefits and drawbacks already mentioned 
related to glucose sensing and insulin infusion, there are a 
number of possible complications and uncertainties 
associated with IP access in general.  
The higher degree of invasiveness of the IP route suggests an 
increased risk of serious infections. For a port based system, 
this risk will mainly be associated with the initial surgical 
procedure for establishing the port, as well as during 
subsequent use and maintenance e.g. during replacement of 
sensor or infusion tubing via the port. More superficial 
infections may occur at the skin-port interface. In the case of 
an implanted insulin pump, similar hazards are associated 
with the initial implantation, and also with subsequent re-
filling of the insulin reservoir, which will take place with a 
syringe through the skin. More seriously, the inevitable need 
for eventually replacing defective componentry implies some 
degree of surgical procedure and the associated hazards. All 
in all it is very likely that the IP route will require more 
frequent visits to a hospital than the SC one, and in particular 
until the technology has matured. A port-based system in 
principle lends itself to more user “self-service” than the 
implanted alternative due to the easier access to internal 
components, but it remains to establish to what extent the 
different procedures can be performed outside of a hospital. 
From a control perspective, the main hazard of an AP is 
hypoglycemia. The preceding sections point to challenges 
associated with using the subcutaneous tissue for glucose 
measurement and insulin infusion. It has been advocated that 
CGMs based on SC sensors perform adequately for use in a 
closed-loop system if sensor calibration and failure is handled 
properly (Keenan et al. 2011). However, the same authors 
point out that the BGL setpoint should be raised to 7.8 
mmol/L at night to reduce the risk of hypoglycemia. This is 
significantly higher than the normal BGL in healthy subjects, 
and likely to be high enough to cause serious long-term 
physiological effects (DCCT/EDIC Research Group et al. 
2015, Hu et al. 2015).  
In contrast, the reduced latency associated with measurement 
and infusion in the peritoneum should allow for increased 
closed-loop bandwidth that would keep the actual BGL 
significantly closer to its setpoint. Consequently, this setpoint 
may be chosen to be closer to the steady-state level for 
healthy individuals, even during the night, without increased 
risk of inducing hypoglycemia. “Impaired fasting glucose” 
(IFG) level is defined as 5.6–6.9 mmol/L by the American 
Diabetes Association (2014) and 6.1–6.9 mmol/L by the 
World Health Organization (2006). It is challenging to define 
a normal fasting glucose level, but it must certainly be lower 
than the IFG level. We advocate that the appropriate goal 
setpoint for an IP AP should be as low as 4.5 mmol/L, with a 
safety constraint that BGL should never exit the range 4.0–
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8.0 mmol/L. This ambitious goal seems to be compatible 
with the physiological realities of IP sensing and infusion 
dynamics, although it may take novel technology to achieve 
it in a practical system.  
Several groups and studies have pointed to the benefits of the 
IP route, and a number of highly different technical solutions 
have been suggested for how to implement a double IP AP. 
Taylor et al. (2010) assessed a fully implantable, completely 
passive device in which the release of insulin was governed 
by the response of a glucose-sensitive material. The device 
quite successfully controlled the BGL of a rat model until the 
insulin reservoir was exhausted. Another fully implantable 
device conceived by Huyett et al. (2015) comprises a glucose 
sensor, a controller running a proportional-integral-derivative 
(PID) algorithm and an active insulin pump. In silico 
experiments indicated its ability to keep BGL within its 
desired range of 4.4–7.8 mmol/L without ever dropping 
below this range, which is compatible with the desired range 
advocated above. 
While these and several of the IIP studies suggest fully 
implanting the device in peritoneum, we believe that access 
through a peritoneal port is a superior option. This will 
reduce the need of higher concentration insulin (with its 
challenges) and simplify re-filling. Obviously, if insulin is 
infused in the peritoneum through a semi-permanent port, this 
access point lends itself to glucose measurements as well. 
Thus, all major components can be placed externally, 
allowing easy access for power supply, inspection and repair. 
Apart from the significant dynamic benefits, the IIP 
alternative has several other benefits of which some will only 
be evident in the long term and thus are only conjectures at 
present. These aspects are discussed briefly below. 
There is some evidence that the higher and more 
physiologically appropriate ratio between insulin reaching the 
liver and that reaching peripheral tissues (Nelson et al. 1982) 
may allow for reduction in total insulin use, which may 
reduce the long-term risk of cardiovascular disease (Hopkins 
2013).  
One of the hormones that increase BGL is glucagon, which is 
produced in the pancreatic alpha cells and seems to be 
coupled in one way or another to the production of insulin. In 
fact glucagon is very important in counteracting 
hypoglycemia. The ability to produce glucagon seems to be 
significantly inhibited early in the lifetime of patients with 
Diabetes Mellitus type 1, and an artificial supply of this 
hormone is indeed included as a second control input in the 
so-called “bionic pancreas” or dual hormone AP (Russell et 
al. 2014). However, a major improvement of glucose control 
towards normoglycemia seems to improve the intrinsic 
production of glucagon in response to hypoglycemia, thereby 
opening the possibility of improving glucose homeostasis 
(Oskarsson et al. 2000). In this way, a well-functioning AP 
may also benefit from the body’s own guard and 
counteraction to avoid hypoglycemia, and thus facilitates the 
possibility to completely normalize glucose levels even 
without the use of exogenous glucagon infusion. 
By conjecture, in the case of a dual hormone AP, an IP 
approach would probably also imply faster absorption of 
glucagon. The hormone would reach the liver at a higher 
concentration and have a more physiological distribution 
throughout the body as compared to the SC route, in much 
the same way as for insulin, thereby further facilitating 
improved glucose control. 
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